MCID: ALZ034
MIFTS: 76

Alzheimer Disease

Categories: Genetic diseases, Rare diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Alzheimer Disease

MalaCards integrated aliases for Alzheimer Disease:

Name: Alzheimer Disease 54 12 23 50 24 25 71 29 42 38
Alzheimer's Disease 38 12 72 25 51 29 41 3 14 69
Ad 12 25 71
Alzheimer Disease 1, Familial 54 13
Presenile and Senile Dementia 25 71
Familial Alzheimer Disease 25 69
Early-Onset Alzheimer Disease with Cerebral Amyloid Angiopathy 71
Alzheimer Disease, Susceptibility to 24
Primary Senile Degenerative Dementia 25
Autosomal Dominant Alzheimer Disease 71
Dementia Due to Alzheimer's Disease 69
Alzheimer's Disease Pathway Kegg 69
Alzheimer Disease, Late-Onset 54
Alzheimer Disease, Familial 12
Alzheimer Disease Type 1 69
Alzheimer-Type Dementia 25
Alzheimers Dementia 12
Alzheimer Disease 1 71
Alzheimer Sclerosis 25
Alzheimer Dementia 25
Alzheimer Syndrome 25
Alzheimers Disease 52
Sdat 25
Ad1 71
Dat 25

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant

Miscellaneous:
genetic heterogeneity


HPO:

32
alzheimer disease:
Inheritance heterogeneous autosomal dominant inheritance


Classifications:



Summaries for Alzheimer Disease

NINDS : 51 Alzheimer's disease (AD) is an age-related, non-reversible brain disorder that develops over a period of years. Initially, people experience memory loss and confusion, which may be mistaken for the kinds of memory changes that are sometimes associated with normal aging. However, the symptoms of AD gradually lead to behavior and personality changes, a decline in cognitive abilities such as decision-making and language skills, and problems recognizing family and friends. AD ultimately leads to a severe loss of mental function. These losses are related to the worsening breakdown of the connections between certain neurons in the brain and their eventual death. AD is one of a group of disorders called dementias that are characterized by cognitive and behavioral problems. It is the most common cause of dementia among people age 65 and older. There are three major hallmarks in the brain that are associated with the disease processes of AD. Amyloid plaques, which are made up of fragments of a protein called beta-amyloid peptide mixed with a collection of additional proteins, remnants of neurons, and bits and pieces of other nerve cells. Neurofibrillary tangles (NFTs), found inside neurons, are abnormal collections of a protein called tau. Normal tau is required for healthy neurons. However, in AD, tau clumps together. As a result, neurons fail to function normally and eventually die. Loss of connections between neurons responsible for memory and learning. Neurons can't survive when they lose their connections to other neurons. As neurons die throughout the brain, the affected regions begin to atrophy, or shrink. By the final stage of AD, damage is widespread and brain tissue has shrunk significantly.

MalaCards based summary : Alzheimer Disease, also known as alzheimer's disease, is related to early-onset, autosomal dominant alzheimer disease and alzheimer disease, type 3, and has symptoms including parkinsonism, dementia and neurofibrillary tangles. An important gene associated with Alzheimer Disease is APP (Amyloid Beta Precursor Protein), and among its related pathways/superpathways is Alzheimer's disease. The drugs Galantamine and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include Brain and Blood.

NIH Rare Diseases : 50 alzheimer disease (ad) is a degenerative disease of the brain that causes gradual loss of memory, judgment, and the ability to function socially. alzheimer disease currently affects about 5 million people. about 75 percent of alzheimer disease cases are classified as sporadic, which means they occur in people with no history of the disorder in their family. although the cause of these cases is unknown, genetic changes are likely to play a role. virtually all sporadic cases of alzheimer disease begin after age 65, and the risk of developing this condition increases as a person gets older. ad can be subdivided into two groups based on the age of onset: (1) early-onset (1%-6% of the cases) which start in people younger than 60- 65 years of age (2) late-onset, which starts in people older than 65 years old. in about 25% of cases, ad is familial (2 or more people in a family have ad). for more information, please visit gard's familial alzheimer disease web page. last updated: 11/2/2015

UniProtKB/Swiss-Prot : 71 Alzheimer disease: Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C- terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. Alzheimer disease 1: A familial early-onset form of Alzheimer disease. It can be associated with cerebral amyloid angiopathy. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death.

MedlinePlus : 41 alzheimer's disease (ad) is the most common form of dementia among older people. dementia is a brain disorder that seriously affects a person's ability to carry out daily activities. ad begins slowly. it first involves the parts of the brain that control thought, memory and language. people with ad may have trouble remembering things that happened recently or names of people they know. a related problem, mild cognitive impairment (mci), causes more memory problems than normal for people of the same age. many, but not all, people with mci will develop ad. in ad, over time, symptoms get worse. people may not recognize family members. they may have trouble speaking, reading or writing. they may forget how to brush their teeth or comb their hair. later on, they may become anxious or aggressive, or wander away from home. eventually, they need total care. this can cause great stress for family members who must care for them. ad usually begins after age 60. the risk goes up as you get older. your risk is also higher if a family member has had the disease. no treatment can stop the disease. however, some drugs may help keep symptoms from getting worse for a limited time. nih: national institute on aging

Genetics Home Reference : 25 Alzheimer disease is a degenerative disease of the brain that causes dementia, which is a gradual loss of memory, judgment, and ability to function. This disorder usually appears in people older than age 65, but less common forms of the disease appear earlier in adulthood.

OMIM : 54
Alzheimer disease is the most common form of progressive dementia in the elderly. It is a neurodegenerative disorder characterized by the neuropathologic findings of intracellular neurofibrillary tangles (NFT) and extracellular amyloid plaques that accumulate in vulnerable brain regions (Sennvik et al., 2000). Terry and Davies (1980) pointed out that the 'presenile' form, with onset before age 65, is identical to the most common form of late-onset or 'senile' dementia, and suggested the term 'senile dementia of the Alzheimer type' (SDAT). Haines (1991) reviewed the genetics of AD. Selkoe (1996) reviewed the pathophysiology, chromosomal loci, and pathogenetic mechanisms of Alzheimer disease. Theuns and Van Broeckhoven (2000) reviewed the transcriptional regulation of the genes involved in Alzheimer disease. (104300)

Disease Ontology : 12 A tauopathy that is characterized by memory lapses, confusion, emotional instability and progressive loss of mental ability and results in progressive memory loss, impaired thinking, disorientation, and changes in personality and mood starting and leads in advanced cases to a profound decline in cognitive and physical functioning and is marked histologically by the degeneration of brain neurons especially in the cerebral cortex and by the presence of neurofibrillary tangles and plaques containing beta-amyloid.

Wikipedia : 72 Alzheimer\'s disease (AD), also referred to simply as Alzheimer\'s, is a chronic neurodegenerative... more...

GeneReviews: NBK1161

Related Diseases for Alzheimer Disease

Diseases in the Alzheimer Disease family:

Alzheimer Disease-4 Alzheimer Disease 17
Alzheimer Disease 12 Alzheimer Disease 6
Alzheimer Disease, Type 3 Alzheimer Disease 18
Alzheimer Disease 9 Alzheimer Disease-2
Alzheimer Disease 8 Alzheimer Disease 16
Alzheimer's Disease 5 Alzheimer's Disease 7
Alzheimer's Disease 10 Alzheimer's Disease 11
Alzheimer's Disease 13 Alzheimer's Disease 14
Alzheimer's Disease 15 Alzheimer's Disease 19
Early-Onset Familial Alzheimer Disease Alzheimer Disease Type 1
Early-Onset, Autosomal Dominant Alzheimer Disease Alzheimer Disease Risk Factor

Diseases related to Alzheimer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)
id Related Disease Score Top Affiliating Genes
1 early-onset, autosomal dominant alzheimer disease 12.4
2 alzheimer disease, type 3 12.2
3 alzheimer disease 6 12.2
4 alzheimer disease 18 12.1
5 alzheimer disease 9 12.1
6 alzheimer disease mitochondrial 12.0
7 immunodeficiency 27b, mycobacteriosis, ad 12.0
8 renal tubular acidosis, distal, ad 12.0
9 alzheimer disease 12 12.0
10 alzheimer disease 8 12.0
11 alzheimer disease-2 12.0
12 early-onset familial alzheimer disease 12.0
13 alzheimer disease type 1 11.9
14 alzheimer disease 17 11.9
15 alzheimer disease 16 11.8
16 keratosis palmoplantaris striata i, ad 11.8
17 alzheimer disease risk factor 11.7
18 familial mediterranean fever, ad 11.7
19 emery-dreifuss muscular dystrophy 2, ad 11.7
20 slowed nerve conduction velocity, ad 11.7
21 spinal muscular atrophy, lower extremity-predominant, 2, ad 11.7
22 emery-dreifuss muscular dystrophy 7, ad 11.7
23 epidermolysis bullosa dystrophica, ad 11.7
24 mitochondrial dna depletion syndrome 12a ad 11.7
25 spinal muscular atrophy, lower extremity-predominant 1, ad 11.7
26 dopa-responsive dystonia; segawa syndrome ad 11.7
27 alzheimer disease-4 11.7
28 hyper-ige recurrent infection syndrome 11.6
29 alzheimer's disease 19 11.5
30 dementia, lewy body 11.4
31 alzheimer's disease 5 11.4
32 alzheimer's disease 7 11.3
33 alzheimer's disease 10 11.2
34 alzheimer's disease 11 11.2
35 alzheimer's disease 15 11.2
36 posterior cortical atrophy 11.1
37 alzheimer's disease 13 11.1
38 alzheimer's disease 14 11.1
39 down syndrome 11.0
40 schizophrenia 11.0
41 slc6a3-related dopamine transporter deficiency syndrome 10.8
42 supranuclear palsy, progressive 10.8
43 frontotemporal lobar degeneration with ubiquitin-positive inclusions 10.8
44 parkinson disease 1 10.6
45 parkinson disease, late-onset 10.6
46 cerebral amyloid angiopathy, dutch, italian, iowa, flemish, arctic variants 10.6
47 dementia, familial, nonspecific 10.6
48 dementia 10.5
49 neuronitis 10.4
50 cerebritis 10.3

Comorbidity relations with Alzheimer Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 54)


Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Acute Kidney Failure
Amnestic Disorder Bronchitis
Bronchopneumonia Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Communicating Hydrocephalus Conduct Disorder
Conjunctivitis Cystitis
Decubitus Ulcer Deficiency Anemia
Delusional Disorder Dental Caries
Dermatomycosis Encephalopathy
Fecal Incontinence Folic Acid Deficiency Anemia
Generalized Atherosclerosis Grn-Related Frontotemporal Dementia
Heart Disease Hypoglycemia
Hypothyroidism Intermittent Explosive Disorder
Intestinal Volvulus Iron Deficiency Anemia
Kidney Disease Kohlschutter-Tonz Syndrome
Latent Syphilis Marasmus
Neurogenic Bladder Nutritional Deficiency Disease
Obstructive Hydrocephalus Ocular Motor Apraxia
Oral Candidiasis Osteoporosis
Paralytic Ileus Paranoid Schizophrenia
Parkinson Disease, Late-Onset Pernicious Anemia
Personality Disorder Protein-Energy Malnutrition
Pyelonephritis Scabies
Schizophrenia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Alzheimer Disease:



Diseases related to Alzheimer Disease

Symptoms & Phenotypes for Alzheimer Disease

Symptoms via clinical synopsis from OMIM:

54

Neurologic- Central Nervous System:
parkinsonism
presenile and senile dementia
long tract signs
neurofibrillary tangles composed of disordered microtubules


Clinical features from OMIM:

104300

Human phenotypes related to Alzheimer Disease:

32 (show all 6)
id Description HPO Frequency HPO Source Accession
1 parkinsonism 32 HP:0001300
2 dementia 32 HP:0000726
3 neurofibrillary tangles 32 HP:0002185
4 alzheimer disease 32 HP:0002511
5 senile plaques 32 HP:0100256
6 long-tract signs 32 HP:0002423

UMLS symptoms related to Alzheimer Disease:


angina pectoris, back pain, headache, myoclonus, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, equilibration disorder, sleeplessness

Drugs & Therapeutics for Alzheimer Disease

Drugs for Alzheimer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 647)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Galantamine Approved Phase 4,Phase 3,Phase 2,Phase 1 357-70-0 9651
2
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120014-06-4 3152
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054
5
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
6
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2 106266-06-2 5073
7
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
8
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 123441-03-2 77991
9
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 113-45-1 4158
10
Levodopa Approved Phase 4 59-92-7 6047
11
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 1 50-78-2 2244
12
Rivaroxaban Approved Phase 4 366789-02-8
13
Ticagrelor Approved Phase 4,Phase 3 274693-27-5 9871419
14
Warfarin Approved Phase 4,Phase 3,Phase 1 81-81-2 6691 54678486
15
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
16
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757
17
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3 71-58-9
18
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3 57-83-0 5994
19
Nicotine Approved Phase 4,Phase 2,Phase 3,Phase 1 54-11-5 942 89594
20
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Early Phase 1 15687-27-1 3672
21
Isoflurane Approved, Vet_approved Phase 4,Phase 1 26675-46-7 3763
22
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1 2078-54-8 4943
23
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
24
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
25
Haloperidol Approved Phase 4,Phase 3 52-86-8 3559
26
Nicergoline Approved Phase 4 27848-84-6 34040
27 Piracetam Approved Phase 4,Phase 2 7491-74-9
28
Cilostazol Approved Phase 4,Phase 2 73963-72-1 2754
29
Ramipril Approved Phase 4 87333-19-5 5362129
30
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
31
Sertraline Approved Phase 4,Phase 2,Phase 3 79617-96-2 68617
32
Pravastatin Approved Phase 4 81093-37-0 54687
33
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
34
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
35
Norepinephrine Approved Phase 4,Phase 1 51-41-2 439260
36
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 1 129722-12-9 60795
37
Acetaminophen Approved Phase 4,Phase 3,Phase 2 103-90-2 1983
38
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
39
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
40
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
41
Nimodipine Approved Phase 4 66085-59-4 4497
42
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
43
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
44
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2 13422-51-0 11953898 5460373 44475014
45
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
46
Rasagiline Approved Phase 4,Phase 2 136236-51-6 3052776
47
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
48
Atenolol Approved Phase 4 29122-68-7 2249
49
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
50
Trandolapril Approved Phase 4 87679-37-6 5484727

Interventional clinical trials:

(show top 50) (show all 2170)

id Name Status NCT ID Phase Drugs
1 Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®) Unknown status NCT00523666 Phase 4 Galantamine (Reminyl®);Placebo/Galantamine (Reminyl®)
2 Donepezil and Memantine in Moderate to Severe Alzheimer's Disease Unknown status NCT00866060 Phase 4 Memantine;Donepezil;Placebo donepezil;Placebo memantine
3 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
4 Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI Unknown status NCT01329601 Phase 4
5 The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD) Unknown status NCT00626613 Phase 4 Risperdal,reminyl
6 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
7 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4 Rivastigmine
8 CALM-AD Unknown status NCT00142324 Phase 4 Donepezil
9 Improving Function, Quality of Life, Glycemia in Diabetics With Dementia Unknown status NCT00792662 Phase 4 Methylphenidate;Placebo
10 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment Unknown status NCT00306124 Phase 4 Levodopa
11 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 Phase 4 l-123 Ioflupane
12 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
13 Memantine for Agitation in Dementia Unknown status NCT00371059 Phase 4 Memantine;Placebo
14 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
15 Gastrodin Prevents Cognitive Decline Related to Cardiopulmonary Bypass Unknown status NCT00297245 Phase 4 cognitive function
16 Memantine for Post-Operative Pain Control Unknown status NCT01041313 Phase 4 Memantine;Placebo
17 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
18 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
19 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease Completed NCT00381381 Phase 4 Donepezil
20 Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease. Completed NCT00731224 Phase 4 Rivastigmine transdermal patch
21 Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors Completed NCT01529619 Phase 4 Rivastigmine transdermal patch
22 Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease Completed NCT02097056 Phase 4 Donepezil HCL
23 Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed NCT00120874 Phase 4 Memantine
24 A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease Completed NCT00035204 Phase 4 galantamine
25 Double Blind Study of Trp01 in Patients With Alzheimer's Disease Completed NCT00202124 Phase 4 Tryptophan
26 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients Completed NCT01948791 Phase 4 ENA713
27 Trial of Carvedilol in Alzheimer's Disease Completed NCT01354444 Phase 4 Carvedilol;Placebo
28 The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease Completed NCT01054976 Phase 4 Galantamine
29 Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease Completed NCT00561392 Phase 4 Rivastigmine 5 and 10 cm^2 patch
30 Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease Completed NCT00476008 Phase 4 Memantine;Placebo
31 Neural Correlates In Mild Alzheimer's Disease Completed NCT00477659 Phase 4 donepezil HCl (Aricept)
32 Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease Completed NCT00104442 Phase 4 Rivastigmine
33 Escitalopram for the Treatment of Depression in Alzheimer's Disease Completed NCT01841125 Phase 4 escitalopram;Placebo
34 A Study to Evaluate Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease Completed NCT01478204 Phase 4
35 Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease Completed NCT00469456 Phase 4 Memantine;placebo
36 The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility Completed NCT00571064 Phase 4 Donepezil HCl
37 A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease Completed NCT01047579 Phase 4 Rivastigmine transdermal
38 A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA) Completed NCT00622713 Phase 4 Rivastigmine transdermal patch
39 A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease Completed NCT00297362 Phase 4 Galantamine hydrobromide
40 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 Completed NCT00948766 Phase 4 Rivastigmine 4.6 mg/24 h (5 cm^2);Rivastigmine 9.5 mg/24 h (10 cm^2);Rivastigmine 13.3 mg/24 h (15 cm^2);Placebo
41 EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD) Completed NCT00230568 Phase 4 Aricept
42 Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE) Completed NCT00867828 Phase 4
43 Memantine for Agitation and Aggression in Severe Alzheimer's Disease Completed NCT00401167 Phase 4 memantine
44 Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease Completed NCT00551161 Phase 4 memantine
45 A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease Completed NCT01122329 Phase 4
46 Electrophysiologic Measures of Treatment Response in Alzheimer Disease Completed NCT00018278 Phase 4 Aricept;Exelon;Nicoderm Patch
47 Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease) Completed NCT00334906 Phase 4 memantine HCl
48 Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease Completed NCT00933608 Phase 4 memantine;Placebo
49 Apathy Associated With Alzheimer's Disease Completed NCT00254033 Phase 4 Dextroamphetamine;Methylphenidate
50 A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease Completed NCT00862940 Phase 4 Memantine;Placebo

Search NIH Clinical Center for Alzheimer Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alzheimer Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alzheimer Disease:
NEUROSTEM
Embryonic/Adult Cultured Cells Related to Alzheimer Disease:
Umbilical cord blood-derived mesenchymal stem/progenitor cells PMIDs: 23293711 22015609

Cochrane evidence based reviews: alzheimer disease

Genetic Tests for Alzheimer Disease

Genetic tests related to Alzheimer Disease:

id Genetic test Affiliating Genes
1 Alzheimer's Disease 29
2 Alzheimer Disease 29 24
3 Alzheimer Disease, Susceptibility to 24 HFE

Anatomical Context for Alzheimer Disease

MalaCards organs/tissues related to Alzheimer Disease:

39
Brain, Testes, Cortex, Eye, Prostate, Breast, Heart
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alzheimer Disease:
id Tissue Anatomical CompartmentCell Relevance
1 Brain Forebrain White Matter Fibrous Astrocyte Cells Potential therapeutic candidate, affected by disease
2 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
3 Brain Forebrain White Matter Myelinating Oligodendrocyte Cells Affected by disease
4 Brain Neocortex Protoplasmic Astrocyte Cells Potential therapeutic candidate, affected by disease
5 Brain Hippocampus Affected by disease

Publications for Alzheimer Disease

Articles related to Alzheimer Disease:

(show top 50) (show all 1462)
id Title Authors Year
1
Pharmacological activation of the Nrf2 pathway by 3H-1, 2-dithiole-3-thione is neuroprotective in a mouse model of Alzheimer disease. ( 28887195 )
2018
2
Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia. ( 28515265 )
2017
3
African American exome sequencing identifies potential risk variants at Alzheimer disease loci. ( 28480329 )
2017
4
Association of dietary cholesterol and egg intakes with the risk of incident dementia or Alzheimer disease: the Kuopio Ischaemic Heart Disease Risk Factor Study. ( 28052883 )
2017
5
Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. ( 28235814 )
2017
6
Association Between Exercise Capacity and Late Onset of Dementia, Alzheimer Disease, and Cognitive Impairment. ( 28082018 )
2017
7
Quantitative EEG After Brain Stimulation and Cognitive Training in Alzheimer Disease. ( 28045857 )
2017
8
Long-term use of opioids for nonmalignant pain among community-dwelling persons with and without Alzheimer disease in Finland: a nationwide register-based study. ( 28092324 )
2017
9
Genetic risk for schizophrenia and psychosis in Alzheimer disease. ( 28461698 )
2017
10
Kinetic Modeling of the Tau PET Tracer (18)F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects. ( 27908967 )
2017
11
Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease. ( 28082052 )
2017
12
The Fall of Sleep K-Complex in Alzheimer Disease. ( 28045040 )
2017
13
Predictive Utility of Marketed Volumetric Software Tools in Subjects at Risk for Alzheimer Disease: Do Regions Outside the Hippocampus Matter? ( 28057634 )
2017
14
Distinguishing Depressive Pseudodementia from Alzheimer Disease: A Comparative Study of Hippocampal Volumetry and Cognitive Tests. ( 28868066 )
2017
15
The transcription factor XBP1 in memory and cognition: Implications in Alzheimer disease. ( 28079229 )
2017
16
Insulin Resistance in Alzheimer Disease: p53 and MicroRNAs as Important Players. ( 28049397 )
2017
17
Astrocyte dysfunction in Alzheimer disease. ( 28467650 )
2017
18
Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. ( 28482211 )
2017
19
Polygenic risk scores in familial Alzheimer disease. ( 28213371 )
2017
20
Alzheimer disease: Blocking HDAC2-Sp3 interaction - a new approach to AD therapy? ( 28849783 )
2017
21
Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. ( 28515434 )
2017
22
Diagnostic Efficacy of Structural MRI in Patients With Mild-to-Moderate Alzheimer Disease: Automated Volumetric Assessment Versus Visual Assessment. ( 28075620 )
2017
23
Apolipoprotein E I/4 and Risk Factors for Alzheimer Disease-Let's Talk About Sex. ( 28846761 )
2017
24
The Rare-Variant Generalized Disequilibrium Test for Association Analysis of Nuclear and Extended Pedigrees with Application to Alzheimer Disease WGS Data. ( 28065470 )
2017
25
Alzheimer disease makes new blood contacts. ( 28473412 )
2017
26
New (benz)imidazolopyridino tacrines as nonhepatotoxic, cholinesterase inhibitors for Alzheimer disease. ( 28485637 )
2017
27
Polygenic hazard scores in preclinical Alzheimer disease. ( 28940650 )
2017
28
Alzheimer disease: Revising the risk of Alzheimer disease in women. ( 28884752 )
2017
29
Type 3 Diabetes Mellitus: A Novel Implication of Alzheimer Disease. ( 28049395 )
2017
30
Investigation of gene expression and serum levels of PIN1 and eNOS with high blood pressure in patients with Alzheimer disease. ( 28506742 )
2017
31
Subjective memory complaints in preclinical autosomal dominant Alzheimer disease. ( 28878053 )
2017
32
The Relationship Between Copper, Iron, and Selenium Levels and Alzheimer Disease. ( 28500578 )
2017
33
Ultra-rare mutations in SRCAP segregate in Caribbean Hispanic families with Alzheimer disease. ( 28852706 )
2017
34
Diagnostic Utility of the Shortened Version of the Wisconsin Card Sorting Test in Patients With Sporadic Late Onset Alzheimer Disease. ( 28859490 )
2017
35
Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology. ( 28319241 )
2017
36
In vivo imaging of prodromal hippocampus CA1 subfield oxidative stress in models of Alzheimer disease and Angelman syndrome. ( 28592637 )
2017
37
Cognitive aging in black and white Americans: Cognition, cognitive decline, and incidence of Alzheimer disease dementia. ( 28863046 )
2017
38
Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies. ( 28499012 )
2017
39
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. ( 28847837 )
2017
40
Gaining Insights into Specific Drug Formulation Additives for Solubilizing a Potential Anti-Alzheimer Disease Drug B4A1. ( 28488401 )
2017
41
Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnestic Alzheimer Disease Dementia. ( 28394771 )
2017
42
Alzheimer disease in 2016: Putting AD treatments and biomarkers to the test. ( 28084326 )
2017
43
Association of traumatic brain injury and Alzheimer disease onset: A systematic review. ( 28506441 )
2017
44
Alzheimer disease: Soluble TREM2 in CSF sheds light on microglial activation in AD. ( 28084325 )
2017
45
The Nature and Natural History of Posterior Cortical Atrophy Syndrome: A Variant of Early-onset Alzheimer Disease. ( 28796011 )
2017
46
Semantic Memory in the Clinical Progression of Alzheimer Disease. ( 28926415 )
2017
47
Neuropsychiatric Features of Neurosyphilis: Frequency, Relationship with the Severity of Cognitive Impairment and Comparison with Alzheimer Disease. ( 28538242 )
2017
48
DNA Methylation Profiles of Selected Pro-Inflammatory Cytokines in Alzheimer Disease. ( 28053004 )
2017
49
Deletion of exons 9 and 10 of the Presenilin 1 gene in a patient with Early-onset Alzheimer Disease generates longer amyloid seeds. ( 28461250 )
2017
50
Synaptic Plasticity, Dementia and Alzheimer Disease. ( 28088900 )
2017